The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 28, 2020
Filed:
Aug. 12, 2016
Applicant:
Incyte Corporation, Wilmington, DE (US);
Inventors:
Jun Pan, Wilmington, DE (US);
Xiaozhao Wang, Wilmington, DE (US);
Joseph Barbosa, Wilmington, DE (US);
Wenqing Yao, Wilmington, DE (US);
Yingda Ye, Wilmington, DE (US);
Assignee:
Incyte Corporation, Wilmington, DE (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/437 (2006.01); C07D 401/14 (2006.01); C07D 231/56 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); A61K 31/416 (2006.01); A61K 31/4184 (2006.01); A61K 31/435 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 235/06 (2006.01); C07D 401/06 (2006.01); C07D 403/06 (2006.01); C07D 405/12 (2006.01); C07D 491/044 (2006.01);
U.S. Cl.
CPC ...
C07D 231/56 (2013.01); A61K 31/416 (2013.01); A61K 31/4184 (2013.01); A61K 31/435 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 235/06 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 405/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/044 (2013.01);
Abstract
The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are modulators/inhibitors of HDACs, such as HDAC8 and are useful in the treatment of HDAC-associated diseases.